Alto Neuroscience (ANRO)

• Market cap: $359M
• 1 day: -4.68%
• 5 days: -14.2%
• 1 month: 77.37%
• 3 months: 279.08%
• 6 months: 393.62%
• Year to date: 164.84%
• 1 year: 212.67%
• 5 years: -43.96%
• 10 years: -43.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Employees: 76